Work

Phase II trial of carfilzomib for metastatic castration-resistant prostate cancer (mCRPC) following androgen pathway inhibitors.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.6_suppl.224

Authors: Gurudatta Naik, Sejong Bae, Mollie R. De Shazo, Pam Dixon, Lynn Merritt, A. Oliver Sartor, Frederick M. Schnell, Guru Sonpavde

Institutions: University of Alabama at Birmingham, Tulane University, Navicent Health, Dana-Farber Cancer Institute

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2791701030

Cites:

Cited by: 4

Related to: 10